

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



"DISCOVER THE LATEST ADVANCEMENT IN GI CARE"



Organized by



Dr. Tejinder Singh
Consultant Medical
Oncologist, Apollo
Cancer Center,
Apollo Hospital,
Mumbai



Dr. Adwaita Gore
Associate Director
Medical Oncologist,
Nanavati Max
Super Speciality
Hospital, Mumbai



Dr. Anil Heroor
Director Surgical
Oncologist Fortis
Hospitals, Mumbai

Saturday - Sunday
20th - 21st
JULY 2024



**SCAN TO
REGISTER**

 **Taj Santacruz, Mumbai**

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Dear Colleagues

In response to the alarming rise in gastrointestinal (GI) cancers, as highlighted by the 2022 review from the Indian Council of Medical Research's National Centre for Disease Informatics and Research, GKCT recognizes the urgent need for concerted efforts in cancer prevention and control. GI cancers, including those affecting the esophagus, stomach, gallbladder, rectum, and pancreas, have become a significant health burden in India, necessitating proactive measures to address this growing concern.

Awareness among patients, dissemination of medical knowledge, and the development of world-class infrastructure are pivotal in reducing the incidence of GI cancers. The trust advocates for a holistic approach to cancer prevention and control, emphasizing the integration of preventive measures into primary healthcare services. By adopting a non-vertical primary healthcare approach, India can effectively track, educate, and support the population in combating GI cancers while striving for universal health coverage.

In line with its commitment Gopalkrishna Charitable Trust is proud to announce the "7th International Annual Review on Gastrointestinal Cancer Update" scheduled for July 20th – 21st at hotel Taj Santacruz Mumbai. This prestigious event aims to consolidate the latest scientific advancements presented in leading GI conferences and journals from the previous year, offering invaluable insights for clinical practice.

Your active participation will make our efforts meaningful and conclusive.

Regards



Dr. Tejinder Singh
Sr. Consultant Medical Oncologist Apollo Cancer Center,
Apollo Hospital, Mumbai



Dr. Adwaita Gore
Associate Director Medical Oncology Nanavati Max Super
Speciality, Mumbai



Dr. Anil Heroor
Director Surgical Oncology, Mumbai



7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Conference Highlights

“7th International Annual Review on GI Cancer, 20th-21st July 2024 Mumbai” will feature a wide array of multi-disciplinary topics of interest, covering cancers of the esophagus and stomach, pancreas and hepatobiliary tract, small bowel and colon, rectum and anal canal. Every year a large number of clinical, translational and basic studies are presented at many conferences, some of which have an impact on practice. It is difficult for even specialised oncologists to keep pace with this information explosion. This meeting will focus on recapitulating the best original scientific data presented at the following conferences of the preceding year.

- ASCO
- ESMO
- ASCO GI
- WORLD GI
- ESMO GI
- JCO
- NEJM
- BJC
- EJSO
- Lancet Oncology
- Journal of GI Oncology
- EJC

The future of GI cancer treatment including: surgery, chemotherapy, molecular therapy, targeted agents in development, immuno-therapies in development, treatment options in early and advanced stage of disease will be reviewed in the pathbreaking articles published in the following journals during the preceding one year.

in the above sessions, we intend to cover surgical, radiation, medical, pathology, biomarkers and imaging issues making this meeting a truly multi-disciplinary one. At the end of every session there will be an expert panel discussion on relevant aspects of therapy from the abstracts and we explore how the data is relevant in clinical practice. The selection of abstracts is based on originality, innovation and potential impact on clinical practice.

Who Should Attend

This update is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, surgical oncologists, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Participants will learn from engaging presentations delivered by thought leaders and by reviewing and discussing realistic and complex scenarios, sharing clinical experiences, understanding well-established and emerging unmet therapeutic opportunities, solving clinical problems, and clarifying best practices. We believe that presentation of the most impactful and important abstracts from all important conferences and leading peer reviewed journals in the preceding year will impact clinical practice.

Regards,
Organising Committee



7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Abstract Submission Guideline

- 1) The scientific committee is inviting the submission of abstracts for the 7th GI Review 2024.
- 2) Registration is mandatory before submission of the abstract. Registration is 1,000/= Rs.
- 3) The abstract must be submitted online at the submission portal only.
- 4) Opportunity for abstract podium Presentations & poster presentations.
- 5) 10 awards to be won for each 10,000/=Rs
- 6) Awards based on organ specialty.
- 7) All abstracts submitted should be original.
- 8) Original research, trials, reviews, and prospective and retrospective series are preferred. Case reports/ series may also be submitted for consideration if there is a significant learning point associated with it.
- 9) The abstract should not exceed 400 words and should be structured as follows:
 - Background • Methods
 - Results
 - Conclusions
- 10) Once the final submission is made under your Name once, no further edits will be entertained. All abstracts will be evaluated and scored by an expert scientific committee. The committee reserves the right to decide if a submitted abstract should be considered for oral presentation. All decisions made by the expert panel will be final and binding and no disputes in this regard will be entertained.
- 11) The presenting author will be notified by email about acceptance and other details
- 12) In case of the author's unavailability for presentation, one of the co-authors may present the work, provided they register for the conference.
- 13) Selected 10 abstracts will get chance to present on 21st July 2024 Sunday between 9:00am to 10.40am in the conference through podium. 10 Minutes each slot. Poster presentation will be review by scientific committee during tea breaks on 20th and 21st July 2024.
- 14) For any query, please contact to annualreviewgicancers@gmail.com
Warm Regards, Scientific Committee

Abstract submission Form

1. Abstract Title
2. Name of Presenting Author
3. Qualification
4. Conference Reg. No
5. Co-Authors (Upto 5)
6. Institute Name
7. Institute City
8. Presenting Author Mobile
9. Presenting Author Email ID
10. Specify if other
11. Abstract File



7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Day
1 20th July 2024

08:30 - 08:55

Registration

08:55 - 09:00

Welcome Address

Dr. Tejinder Singh, Dr. Adwaita Gore, Dr. Anil Heroor

Session 1 Esophagus

Chairpersons : Dr. Sanjay Dudhat

09:00 - 09:15

First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.

Speaker : Dr. Parikshit J

A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.

Speaker : Dr. Sowmica Devabhaktuni

Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.

Speaker : Dr. Darshit Shah

09:15 - 09:30

SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).

Speaker : Dr. Shurti Aroa

TBD

Speaker : TBD

TBD

Speaker : TBD

09:30 - 09:40

A randomized controlled phase III trial comparing thoroscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial).

Speaker : Dr. Nikhil Dharmadhikari

TBD

Speaker : TBD

09:40 - 10:00

Sponsored Session - MSD



Phone : 9988463222



Website : www.keyson.in



Email : practice-events@keyson.in

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



10:00 - 10:20

Case Based Panel Discussion: Esophageal cancers

Moderator - Dr. Vivek Agarwala

Panelists:

Dr. Indoo Ammbulkar, Dr. Parikshit J, Dr. Sowmica Devabhaktuni, Dr. Darshit Shah, Shruti Arora
Dr. Nikhil Dharmadhikari, Dr. Tanveer Majeed, Dr. Kiran Tamkhane, Dr. Shirish Alurkar

Session 2 Gastric cancers

Chairpersons : Dr. Raghunath Rao, Dr. Chandrashekhar Pathe

10:20 - 10:35

A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study).

Speaker : Dr. Mubarakunnisa Tonse

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.

Speaker : Dr. Goli Vasu

Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.

Speaker : Dr. Varun Nagori

10:35 - 10:50

Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.

Speaker : Dr. Amol Kotalwar

TBD

Speaker : TBD

LBA4 - Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase 3 trial

Speaker : Dr. Honey Parekh

10:05 - 11:05

Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.

Speaker : Dr. Ambarish Chatterjee

ASO Visual Abstract: Palliative Surgery for Patients with Gastroesophageal Junction or Gastric Cancer
A Report on Clinical Observational Outcomes

Speaker : Dr. Aditiya Punaminy

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



11:05 - 11:25

Case Based Panel Discussion: Gastric cancers

Moderator - Dr. Satheesh CT

Panelist -

Dr. Avinash Deo, Dr. Chetna Bakshi, Dr. Prabhat Bhargava, Dr. Bharat Bhosale, Dr. Mubarakunnisa Tonse, Dr. Goli Vasu, Dr. Varun Nagori, Dr. Amol Kotalwarkar, Dr. Ambarish Chaterjee, Dr. Honey Parekh, Dr. Aditiya Punaminya

11:25 - 11:40

Role of AI in Oncology

Speaker : Dr. Purvish Parikh

Session 3 Hepatobiliary Cancer

Chairpersons : Dr. Bharat Parikh, TBA

11:40 - 11:55

Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.

Speaker : Dr. Roshni Pande

Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).

Speaker : Dr. Madhura Agre

TBD

Speaker : TBD

11:55 - 12:10

TBD

Speaker : TBD

TBD

Speaker : TBD

TBD

Speaker : TBD

12:10 - 12:30

Panel Discussion: Hepato Biliary cancers

Moderator - Dr. Rejiv Rajendranath

Panelist -

Dr. Darshana Rane, Dr. Jyoti Bajpai, Dr. Chetan Deshmukh, Dr. Madhura Agre, Dr. Roshni Pande

12:30 - 12:50

The role of cyramza in second line gastric cancer (Supported By Eli Lilly)

Speaker : Dr. Akhil Kapoor



Phone : 9988463222



Website : www.keyson.in



Email : practice-events@keyson.in

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



12:50 - 13:00

Session Supported By INTAS

Speaker : TBD

13:00 - 13:25

Lunch Break

Session 4 Pancreatic Cancer

Chair Person : Josheph Sequeira

13:25 - 13:40

Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).

Speaker : Dr. Kaushal Patel

Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.

Speaker : TBD

Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.

Speaker : Dr. Gayatri Raheja

13:40 - 14:00

Panel Discussion: Pancreas

Moderator - Dr. Peush Bajpai

Panelist -

Dr. Kaushal Patel, Dr. Gayatri Raheja, TBA

Session 5 Colorectal Cancer

Chairpersons : Dr. Tapan Saikia, Dr. Ramakant Deshpande

14:00 - 14:15

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

Speaker: Dr. Saadvik Raghuram

Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

Speaker: TBA

Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).

Speaker: Dr. Devendra Pal

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



14:15 - 14:30

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

Speaker: Dr. Pushkal Dwivedi

Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)

Speaker : Dr. Iti Parekh

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

Speaker : Dr. Ashwin Rajbhog

14:30 - 14:45

Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: A multi-institutional prospective study.

Speaker : Dr. Jayesh Gori

TBD

Speaker : TBD

14:45 - 15:05

Panel Discussion: Colorectal cancer (Adjuvant)

Moderator - Dr. Viraj Lavingia

Panelist -

Dr. Muzammil Shaikh, Dr. Anjana Sainani, Dr. Saadvik Raghuram, Dr. Jayesh Gori, Dr. Devendra Pal

15:05 - 15:25

Panel Discussion: Colorectal cancer (Metastatic)

Moderator - Dr. T.P.Sahoo

Panelist -

Dr. Sunil Chopade, Dr. Avinash Talele, Dr. Vijay Sharnagat, Dr. Uma Dangi, Dr. Pushkal Dwivedi, Dr. Iti Parekh, Dr. Ashwin Rajbhog

15:25 - 15:45

Sponsored Session By MSD

15:45 - 16:00

Role of CGP in the Management of GI Malignancies - Guardant (Session Supported by Zydus)

Session 6 Neuro Endocrine Tumors

TBA, TBA

16:00 - 16:15

NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).

Speaker : Dr. Dinky Gajiwala

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Speaker: Dr. Pritam Kataria

Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.

Speaker: Dr. Kunal Jobanputra

16:15 - 16:30

TBD

Speaker : TBD

TBD

Speaker : TBD

TBD

Speaker : TBD

16:30 - 16:50

Panel Discussion: Neuro endocrine cancers

Moderator - Dr. Suman Mittal

Panelist -

Dr. Kunal Jobanputra, Dr. Suchita Pathak,
Dr. Dinky Gajiwala, Dr. Pritam Kataria, Dr. Jeyhan Dhabhar

16:30 - 19:00

Sponsored Sessions

Sponsored Session 1

Sponsored Session 2

Sponsored Session 3

Sponsored Session 4

Sponsored Session 5

Sponsored Session 6

Followed by Gala Dinner

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Day
2 21st July 2024

07:45 - 08:00

Registration

Paper Presentation

08:00 - 08:10

Abstract Presentation by Medical Onc

Speaker :TBD

08:10 - 08:20

Abstract Presentation by Medical Onc

Speaker :TBD

08:20 - 08:30

Abstract Presentation by Surgeon

Speaker :TBD

08:30 - 08:40

Abstract Presentation by Surgeon

Speaker :TBD

08:40 - 08:50

Abstract Presentation by Radiation Onc

Speaker :TBD

08:50 - 09:00

Abstract Presentation by Medical Onc

Speaker :TBD

09:00 - 09:10

Abstract Presentation by Medical Onc

Speaker :TBD

09:10 - 09:20

Abstract Presentation by Surgeon

Speaker :TBD

09:20 - 09:30

Abstract Presentation by Medical Onc

Speaker :TBD

09:30 - 09:40

Abstract Presentation by Medical Onc

Speaker :TBD

09:40 - 09:50

Abstract Presentation by Medical Onc

Speaker :TBD

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



09:50 - 10:00

TEA BREAK

Upper GI - Chair Persons

Chair Persons - TBD

10:00 - 10:15

Radical D2 Gastrectomy Video Lecture

Speaker : Dr. Devendra Parikh

10:15 - 10:45

GE Junction lesion - which is the right Surgery - Panel Discussion

Speaker : Dr. Arvind Krishnamurthy

10:45 - 11:00

Impact of ICG during Esophagectomy

Speaker : Dr. Srijan Shukla

Pancreas

11:00 - 11:15

Laparoscopic whipple

Speaker : Dr. Jitendra Rohila

11:15 - 11:30

Extended resections for pancreatic cancer - Is it worth the effort?

Speaker : TBD

11:30 - 11:45

Laparoscopic radical cholecystectomy

Speaker : TBD

11:45 - 12:00

Robotic right hepatectomy

Speaker : TBD

Lower GI

12:00 - 12:15

Robotic ISR Video Lecture

Speaker : Dr. Sandeep Nayak

12:15 - 12:30

ISR Vs APR Debate

Speaker : APR - Dr. Shaikat Gupta, ISR - Mufaddal Kazi

12:30 - 13:00

Panel Discussion: Multivisceral resection / Locally advanced CRC

Moderator - Dr. Sujai Hegde

Panelists:

Panelist: Dr Vikas Gupta, Dr Harshit Shah, Dr Yogen Chedda, Dr Rajesh Shinde

Followed by Gala Dinner

7TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER



Meet Our Partners

	<p>Dedicated To Life</p>	
	<p>SUCCESS THROUGH INNOVATION</p>	
<p>POWER OF EMPATHY TRUTH OF SCIENCE</p>	<p>A new way for a new world</p>	
		<p>PHARMACEUTICAL COMPANIES OF Johnson-Johnson</p>